NCT06425081View on ClinicalTrials.gov

Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The VIAB2L Project)

NACompletedINTERVENTIONAL

Enrollment

185

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions

Microbial Colonization

Interventions

DIETARY_SUPPLEMENT

Limosilactobacillus reuteri AMBV339

Limosilactobacillus reuteri AMBV339 is a probiotic strain

DIETARY_SUPPLEMENT

Humiome B2

Colon-delivered Riboflavin

DIETARY_SUPPLEMENT

Limosilactobacillus reuteri AMBV339 + Humiome B2

Combination of supplements used in arm 1 and 2

DIETARY_SUPPLEMENT

Placebo

Microcrystalline cellulose

Trial Locations (1)

2020

Lab of Applied Microbiology and Biotechnology, University of Antwerp, Antwerp

All Listed Sponsors

collaborator

Universiteit Antwerpen

OTHER

lead

DSM Nutritional Products, Inc.

INDUSTRY

NCT06425081 - Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The VIAB2L Project) | Biotech Hunter | Biotech Hunter